Microsatellite analysis in serous tumors of the ovary

International Journal of Gynecological Pathology

Volumn 18, Issue 2, 1999, Pages 158-162

  Haas, Christian J ^a,b   Diebold, Joachim ^a   Hirschmann, Astrid ^a   Rohrbach, Helmut ^a   Schmid, Sabine ^a   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

Loss of heterozygosity; Low malignant potential; Microsatellite instability; Serous ovarian tumors

Indexed keywords

ARTICLE; CARCINOGENESIS; CELL HETEROGENEITY; GENE LOCUS; HUMAN; HUMAN TISSUE; MICROSATELLITE INSTABILITY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL;

EID: 0032999940     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199904000-00010     Document Type: Article

References (39)

1. Kurman RJ, Trimble CL, The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120-7.
2. Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 1993;67:551-9.
3. Rodabaugh KJ, Blanchard G, Welch WR, Bell DA, Berkowitz RS, Mok SC. Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors. Cancer Res 1995;55:2169-72.
4. Diebold J, Deisenhofer I, Baretton GB, et al. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas. Lab Invest 1996;75:473-85.
5. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331-45.
6. Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res 1992;20:1427.
7. Rosen DR, Brown RH, Jr. Dinucleotide repeat polymorphism in the HOX4E locus. Hum Mol Genet 1993;2:617.
8. Gyapay G, Morissette J, Vignal A, et al. The 1993-94 Genethon human genetic linkage map. Nat Genet 1994;7:246-339.
9. Sanguinetti CJ, Dias Neto E, Simpson AJ. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994;17:914-21.
10. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995;75: 270-94.
11. Hölzel D, Klamert A, Schmidt M, Krebs. Häufigkeiten, Befunde und Behandlungsergebnisse. Perspektiven für die Krebsdiskussion und eine quantitative klinisch-epidemiologische Onkologie aus dem Tumorregister München. Munich: W. Zuckerschwerdt, 1996.
12. Chuaqui RF, Zhuang Z, Merino MJ. Molecular genetic events in the development and progression of ovarian cancer in humans. Mol Med Today 1997;3:207-13.
13. McCluskey LL, Dubeau L. Biology of ovarian cancer. Curr Opin Oncol 1997;9:465-70.
14. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-63.
15. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
16. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645-8.
17. Lothe RA. Microsatellite instability in human solid tumors. Mol Med Today 1997;3:61-8.
18. Tangir J, Loughridge NS, Berkowitz RS, Muto MG, Bell DA, Welch WR, Mok SC. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 1996;56:2501-5.
19. Tomlinson IP, Ilyas M, Bodmer WF. Allele loss occurs frequently at hMLH1, but rarely at hMSH2, in sporadic colorectal cancers with microsatellite instability. Br J Cancer 1996;74:1514-7.
20. Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS, Inoue M, Okudaira Y. Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 1995;64: 361-6.
21. Arzimanoglou II, Lallas T, Osborne M, Barber H, Gilbert F. Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 1996;17:1799-1804.
22. Cheng PC, Gosewehr JA, Kim TM, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 1996;88:510-8.
23. Choi C, Cho S, Horikawa I, et al. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer 1997;20:234-42.
24. Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 1997;16:197-202.
25. Roy WJ, Jr, Watson RH, Hitchcock A, Campbell IG. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours. Oncogene 1997;15:2031-35.
26. Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB, Sidransky D. Frequent microsatellite instability in primary small cell lung cancer. Cancer Res 1994;54:2098-2101.
27. Mironov NM, Aguelon MA, Potapova GI, Omori Y, Gorbunov OV, Klimenkov AA, Yamasaki H. Alterations of (CA)n DNA repeats and tumor suppressor genes in human gastric cancer. Cancer Res 1994:54:41-4.
28. Yee CJ, Roodi N, Verrier CS, Pari FF. Microsatellite instability and loss of heterozygosity in breast cancer. Cancer Res 1994;54: 1641-44.
29. Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Löhrs U. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Virchows Arch (in press).
30. Yang Feng TL, Han H, Chen KC, et al. Allelic loss in ovarian cancer. Int J Cancer 1993;54:546-51.
31. Osborne RJ, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994;69:429-38.
32. King BL, Carcangiu ML, Carter D, Kiechle M, Pfisterer J, Pfleiderer A, Kacinski BM. Microsatellite instability in ovarian neoplasms. Br J Cancer 1995;72:376-82.
33. Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol 1982;1:3-16.
34. Elchalal U, Dgani R, Piura B, Anteby SO, Zalel Y, Czernobilsky B, Schenker JG. Current concepts in management of epithelial ovarian tumors of low malignant potential. Obstet Gynecol Surv 1995;50:62-70.
35. Wolf NG, Abdul Karim FW, Schork NJ, Schwartz S. Origins of heterogeneous ovarian carcinomas: a molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components. Am J Pathol 1996;149:511-20.
36. Chenevix-Trench G, Kerr J, Hurst T, et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer 1997;18: 75-83.
37. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 sene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-51.
38. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:387-92.
39. Arzimanoglou II, Gilbert F, Barber HR. Microsatellite instability in human solid tumors. Cancer 1998;82:1808-20.